Influences of the Diffusion of Psychotropic Medications

精神药物传播的影响

• 批准号: 6989750
• 负责人: MARISA ELENA DOMINO
• 金额: $ 14.68万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-12-01 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6989750
• 关键词: behavioral /social science research tag; chemical registry /resource; clinical research; consumer product; decision making; drug controls; drug quality /standard; health administration; health behavior; health care policy; health care service availability; health care service utilization; health economics; health insurance; human data; managed care; psychopharmacology; psychotropic drugs; user protection

DESCRIPTION (provided by applicant): This application seeks a career development award for training in pharmaceutical institutions and policies, psychiatric clinical decision-making and psychopharmacology in order to inform economic research on psychotropic medications. The award period includes 3 research aims to characterize the diffusion of new psychotropic medications across a range of insurance settings, both managed and non-managed care, nationally and in several local markets in an effort to understand the inhibitors and promoters of the adoption and diffusion rate of new pharmaceutical technologies. The specific research aims of this application are 1) to describe major aggregate patterns of diffusion of principal new drugs for the treatment of behavioral health disorders, 2) to determine whether market characteristics and characteristics of psychotropic drug products and their competitors influence the diffusion of drugs at the market (aggregate) level, and 3) to develop and test behavioral models of drug diffusion at the individual level. The training and research activities will enable the candidate to synthesize current research and institutional knowledge from the pharmaceutical industry, pharmaceutical promotion efforts, and clinical literature with a theoretical framework from the discipline of economics in order to begin an important line of inquiry largely missing from the current mental health services research literature. Four mentors with expertise in areas critical to this project have been selected. Dr. Dale Christensen, professor and chair of the Dept. of Pharmaceutical Policy and Evaluative Sciences at UNC will serve as the primary mentor, providing guidance on pharmaceutical policy and marketing. Dr. Ernst Berndt, Professor of Economics at MIT, Dr. Richard Frank, Professor at Harvard and Dr. Marvin Swartz, professor of Psychiatry and Behavioral Sciences at Duke will serve as additional research advisors. The diffusion of new behavioral health technologies has been very uneven. Some psychotropic medications have diffused very quickly while others have not had much success developing a substantial market share. In order to advance models of best practice, it is important to understand the factors that underlie these varying rates of diffusion. Training in the area of pharmaceutical policy and the relevant clinical context will allow the investigator to develop a long-term research plan to study the factors that encourage or impede access to important new technologies.

描述(申请人提供)：该申请寻求职业发展奖的培训，在制药机构和政策，精神病学临床决策和精神药理学，以提供有关精神药物的经济研究。获奖期包括3项研究，旨在描述新精神药物在一系列保险环境中的传播特征，包括管理和非管理的医疗保健，以及在全国和几个地方市场的传播，以努力了解新制药技术采用和传播速度的抑制和促进因素。本申请的具体研究目标是：1)描述治疗行为健康障碍的主要新药的主要聚集模式；2)确定精神药物产品及其竞争对手的市场特征和特征是否影响市场(聚集)层面的药物扩散；3)开发和测试个体层面的药物扩散行为模型。培训和研究活动将使应聘者能够将制药行业、药物推广工作和临床文献的当前研究和机构知识与经济学学科的理论框架相结合，以便开始一条在当前精神健康服务研究文献中基本上缺失的重要调查路线。已经选出了四名在对该项目至关重要的领域具有专业知识的导师。戴尔·克里斯滕森博士，教授兼系主任。北卡罗来纳大学的药物政策和评估科学部将担任主要导师，提供药物政策和营销方面的指导。麻省理工学院经济学教授恩斯特·伯恩特博士、哈佛大学教授理查德·弗兰克博士和杜克大学精神病学和行为科学教授马文·斯沃茨博士将担任额外的研究顾问。新的行为健康技术的传播一直非常不均衡。一些精神药物传播得非常快，而另一些药物在开发相当大的市场份额方面并没有取得太大成功。为了推进最佳实践的模型，重要的是要了解这些不同扩散速度背后的因素。药物政策领域和相关临床背景方面的培训将使调查员能够制定长期研究计划，研究鼓励或阻碍获得重要新技术的因素。